Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lymphoma: early trial launches for drug SAR448501

NCT ID NCT06392477

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 20 times

Summary

This early-phase study tests a new drug, SAR448501, in about 96 adults with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. Participants will receive the drug for up to a year and be followed for about three years total.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational Site Number : 001-201

    RECRUITING

    Perth, Western Australia, 6009, Australia

  • Investigational Site Number : 001-202

    RECRUITING

    Townsville, Queensland, 4814, Australia

  • Investigational Site Number : 001-203

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Investigational Site Number : 001-204

    RECRUITING

    Melbourne, Victoria, 3121, Australia

  • Investigational Site Number : 001-205

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Investigational Site Number : 001-401

    RECRUITING

    Busan, 48108, South Korea

  • Investigational Site Number : 001-402

    RECRUITING

    Seoul, 03080, South Korea

  • Investigational Site Number : 001-403

    RECRUITING

    Busan, 49201, South Korea

  • Investigational Site Number : 001-404

    RECRUITING

    Goyang-si, 10408, South Korea

  • Investigational Site Number : 001-405

    RECRUITING

    Seoul, 06351, South Korea

  • Investigational Site Number : 001-501

    RECRUITING

    Taipei, 10048, Taiwan

  • Investigational Site Number : 001-502

    RECRUITING

    Kaohsiung City, 83301, Taiwan

  • Investigational Site Number : 001-503

    RECRUITING

    Changhua, 505, Taiwan

  • Investigational Site Number : 001-601

    RECRUITING

    Singapore, 119074, Singapore

  • Investigational Site Number : 001-602

    RECRUITING

    Singapore, 308433, Singapore

  • Investigational Site Number : 001-703

    ACTIVE_NOT_RECRUITING

    Kamenitz, 21204, Serbia

Conditions

Explore the condition pages connected to this study.

B-CELL NON HODGKIN LYMPHOMA B-CELL NON HODGKIN LYMPHOMA